ISRCTN14019493进行中（未招募）Unknown
A randomised, double-blind, parallel group, placebo controlled, trial of Bactek for the prevention of lower respiratory tract infections in preterm infants
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 入组人数
- 542
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Birth at gestational age =29+6 weeks (including infants born as one of a multiple births)
- •2. In the opinion of the PI, follow-up is likely to be feasible (i.e routine outpatient appointments will be at the recruiting site, locality of baby’s residence so follow up to one year corrected age is possible.)
- •3. Survival to 1 year corrected of age is anticipated
排除标准
- •1. Presence of major surgical, cardiac or congenital abnormalities (not including patent ductus arteriosus or patent foramen ovale)
- •2. Contraindication of Bactek™ as specified in the Investigator’s Brochure
- •3. Participation in other interventional trial that precludes participation in BALLOO
研究者
相似试验
进行中（未招募）
1 期
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.Adjuvant breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003839-30-DEAstraZeneca AB1,800
已完成
3 期
A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.Breastcancer10006232NL-OMON47654Astra Zeneca40
进行中（未招募）
不适用
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.Adjuvant breast cancerMedDRA version: 17.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003839-30-ESAstraZeneca AB1,320
进行中（未招募）
1 期
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.Adjuvant breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003839-30-NLAstraZeneca AB1,800
进行中（未招募）
1 期
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.EUCTR2013-003839-30-BEAstraZeneca AB1,800